Research Article Details
| Article ID: | A07932 |
| PMID: | 32306650 |
| Source: | Zhonghua Gan Zang Bing Za Zhi |
| Title: | [Emphasis on clinical study of heterogeneity of non-alcoholic fatty liver disease]. |
| Abstract: | Nonalcoholic fatty liver disease is the leading cause of chronic liver disease worldwide. Non-alcoholic fatty liver disease has a wide spectrum of diseases including simple fatty liver, steatohepatitis, liver fibrosis, and cirrhosis. The clinical manifestations and disease outcomes of patients with non-alcoholic fatty liver disease vary widely, and are related to the heterogeneity of risk factors, such as heredity, epigenetics, race, gender, age, diet, exercise, alcohol drinking, intestinal microecology, coexisting diseases, and hormone and metabolic status. Emphasizing the study of pathogenesis and clinical heterogeneity of patients with non-alcoholic fatty liver disease will help to layer the management of disease and improve the effectiveness of clinical trials. |
| DOI: | 10.3760/cma.j.cn501113-20200317-00119 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|